about
Protein tyrosine kinase 7 has a conserved role in Wnt/β-catenin canonical signallingMinimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendationsA phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes.Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes.Patterns of Venous Thromboembolism Prophylaxis During Treatment of Acute Leukemia: Results of a North American Web-Based Survey.Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia.Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des MyelodysplasiesRisk stratification in myelodysplastic syndromes: is there a role for gene expression profiling?Planctomycetes DNA in febrile aplastic patients with leukemia, rash, diarrhea, and micronodular pneumonia.Overexpression of the Promigratory and Prometastatic PTK7 Receptor Is Associated with an Adverse Clinical Outcome in Colorectal CancerDasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial.Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure.Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia.Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.Vorinostat in acute myeloid leukemia and myelodysplastic syndromes.Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor ActivityA randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities.Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.Chronic myelomoncytic leukemia: Are we finally solving the identity crisis?Trends in Clinical Investigation for Myelodysplastic Syndromes.Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings.A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure.Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings.The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcome.Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes.Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States.Incidence of ATRX mutations in myelodysplastic syndromes, the value of microcytosis.Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities.An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemiaOutcome of patients with low-risk myelodysplasia after azacitidine treatment failure.Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring systemAnti-leukemia activity of chaetocin via death receptor-dependent apoptosis and dual modulation of the histone methyl-transferase SUV39H1.Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia.Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia.A simplified, 96-well-adapted, ATP luminescence-based motility assay.Impact of reduced-intensity conditioning allogeneic stem cell transplantation on women's fertility.Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemia.Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies.
P50
Q24313083-C3760CDC-7D62-43F2-894E-F38B70617174Q26865362-390E7BBB-520A-4970-B00F-ACA9178C9B04Q33361012-75421F7E-4DF3-4F31-B1BE-F9380CCF8683Q33409859-33238DEE-E9C3-42B7-BD61-6BAE8863E0AAQ33425797-AC6A5673-5F35-419B-AA52-785BE73E8803Q33437309-D72A7585-9415-43B9-8C1B-339F76645D17Q33518976-C3036F32-7598-4672-8FD3-1C90EAB492ADQ34013786-286D15B0-799F-4386-BA80-7B83EDC504B7Q34424330-915363AF-32CF-4874-A7F5-32CDDFE3760EQ35593473-BCD9EEC7-5FBC-4438-92DD-0AD8406AF305Q35669870-B081977F-40D0-4ADF-A1D5-9FA1AE84F7A6Q36692756-F3AEBE3C-8A26-4D60-8EF8-37FB4DDA0D17Q37158530-BCE017F8-9463-4427-BABB-5468A53A5540Q37362705-3C56BACA-2A5B-4653-B8A2-6BEEC68F40BEQ37702336-ED6CD91F-01B2-444E-9491-0A1D9DFBA1AAQ37824712-2121C0BF-07BC-4ED7-8341-07B9D1D84EBDQ38203261-133391E1-6185-46E0-B7F5-753D84DA3697Q38392081-C55FC69D-74FE-455E-9EF1-F3D82F8D13E1Q38687894-C2363E38-4A7A-4521-A57E-44EE01E8DE79Q38710509-80A8A79C-32E7-42DD-BEFB-0F7CB3E2A215Q38830671-9B6333BC-FD8A-4886-91FA-A0D9C70F816EQ38831689-9EF5AC8E-0904-4860-A4E7-47CCBE3FCF0FQ38961023-06D42366-826D-4846-9141-C1432B6CCC2DQ39089892-CA2ABF59-8F63-4520-BCD3-32191C544550Q39413114-0AE5599A-3BB6-4457-B792-B137AC7FD439Q39691348-3D833E79-662A-494E-9D39-1B2A664A9B2AQ40572555-73B94853-1896-4C7E-A4A8-054D6E0B12EAQ40608642-EF54E3BE-5B9C-4FED-B847-98405D3F179DQ40897451-B6D612A4-054B-449A-B37C-74BD27F278D4Q41640013-39F1BAF1-1060-4097-94FC-DBD7378080C7Q41819724-AFFDBB1E-5A25-4330-A6A3-D676EDF0694BQ41956956-1AAE464F-3264-4570-824D-E58EF23B3578Q42388532-E57F7D20-4A23-4202-8475-781E7741E739Q42726197-84449E8A-D74E-4F78-843D-FDDD98A17F8DQ42923390-2AEE7758-E755-416D-887F-64FBCBAB0DACQ43155337-2CF723F1-3201-4AB1-8DC4-8E388A227875Q43255953-8F48A6CB-3787-4526-B692-C14BD2AD7010Q44143969-A6A041B6-D039-4D57-85CF-2D193A7C83FEQ45340990-3214B4E7-DC4F-4EA5-98B7-67F7FD112DF8Q45590320-F0F09126-2504-4813-A223-84EE9F653443
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Thomas Prebet
@ast
Thomas Prebet
@en
Thomas Prebet
@es
Thomas Prebet
@nl
Thomas Prebet
@sl
type
label
Thomas Prebet
@ast
Thomas Prebet
@en
Thomas Prebet
@es
Thomas Prebet
@nl
Thomas Prebet
@sl
prefLabel
Thomas Prebet
@ast
Thomas Prebet
@en
Thomas Prebet
@es
Thomas Prebet
@nl
Thomas Prebet
@sl
P214
P106
P1153
14010169800
P21
P213
0000 0003 5669 2715
P214
P31
P496
0000-0002-6872-625X
P734
P735
P7859
viaf-188541461